Rigel Pharmaceuticals RIGL

NAS: RIGL | ISIN: US7665596034 22/01/2025

21,81 USD (0,00%)

(0,00%) 22/01/2025

Grafiek Rigel Pharmaceuticals

Grafiek Rigel Pharmaceuticals

1 dag1d 0,00%
1 week1w 25,71%
1 maand1m 27,17%
3 maanden3m 49,49%
6 maanden6m 107,12%
1 jaar1j 1.617,32%
5 jaar5j 723,02%

Rigel Pharmaceuticals in het nieuws

Toon enkel gratis nieuws

12 september 2024 · Rigel to Present at the 2024 Cantor Global Healthcare Conference · Persbericht

5 september 2024 · Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA® (olutasidenib) in mIDH1 AML · Persbericht

3 september 2024 · Rigel Expands Relationship with Kissei to include REZLIDHIA® (olutasidenib) in Japan, the Republic of Korea and Taiwan · Persbericht

29 augustus 2024 · Rigel to Participate in Upcoming September Investor Conferences · Persbericht

6 augustus 2024 · Rigel Reports Second Quarter 2024 Financial Results and Provides Business Update · Persbericht

30 juli 2024 · Rigel Announces Conference Call and Webcast to Report Second Quarter 2024 Financial Results and Business Update · Persbericht

12 juli 2024 · Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) · Persbericht

25 juni 2024 · Rigel Announces Reverse Stock Split · Persbericht

24 juni 2024 · Rigel Pharmaceuticals Completes Transfer of GAVRETO® (pralsetinib) New Drug Application · Persbericht

14 juni 2024 · Rigel Announces Five Presentations at the EHA2024 Hybrid Congress · Persbericht

Profiel Rigel Pharmaceuticals

Fabricage van farmaceutische preparaten

Gezondheidstechnologie

Website: www.rigel.com

Hoofdzetel: South San Francisco, California Verenigde Staten

CEO: Raul Rodriguez

Werknemers: 280

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe